Evidence map›Paper›PMID 34094832›Full record

ArticleActa pharmaceutica Sinica. B2021

SMYD3-PARP16 axis accelerates unfolded protein response and mediates neointima formation.

Fen Long, Di Yang, Jinghua Wang, Qing Wang, Ting Ni, Gang Wei, Yizhun Zhu, Xinhua Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Emerging role of IRE1α in vascular diseases.Journal of cell communication and signaling · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. New insights of epigenetics in vascular and cellular senescence.Journal of translational internal medicine · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Fen LongPharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.
Di YangPharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.
Jinghua WangPharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.
Qing WangPharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.
Ting NiState Key Laboratory of Genetic Engineering & MOE Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center of Genetics and Development, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200438, China.
Gang WeiState Key Laboratory of Genetic Engineering & MOE Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center of Genetics and Development, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200438, China.
Yizhun ZhuState Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Macau, China.
Xinhua LiuPharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.
Fudan University · CNMacau University of Science and Technology · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neointimal hyperplasia after vascular injury is a representative complication of restenosis. Endoplasmic reticulum (ER) stress-induced unfolded protein response (UPR) is involved in the pathogenesis of vascular intimal hyperplasia. PARP16, a member of the poly(ADP-ribose) polymerases family, is correlated with the nuclear envelope and the ER. Here, we found that PERK and IRE1

Indexed as

ATF6, activating transcription factor 6BIP, immunoglobulin heavy-chain binding proteinChIP-seq, chromatin immunoprecipitation coupled with deep sequencingDAPI, 4′,6-diamidino-2-phenylindoleECM, extracellular matrixEGCG, epigallocatechin-3-gallateEndoplasmic reticulumER, endoplasmic reticulumH3K4, histone H3 lysine 4IACUC, Institutional Animal Care and Use CommitteeIRE1, inositol-requiring enzyme 1MMP, matrix metal proteinaseNeointimal hyperplasiaPARP16PARP, poly(ADP-ribose) polymerasesPCNA, proliferating cell nuclear antigenPDGF, platelet-derived growth factorp-eIF2α, phosphate-eukaryotic initiation factor 2αPERK, protein kinase R (PKR)-like ER kinasep-PERK, phosphate-PKR-like ER kinasesiRNA, small interfering RNASMCs, smooth muscle cellsSMYD3SMYD3, SET and MYND domain containing 3UPR, unfolded protein responseVascular smooth muscle cellVCAM-1, vascular cell adhesion molecule-1VSMCs, vascular smooth muscle cellsXBP-1, X-box binding protein-1

Identifiers

PMID34094832
PMCPMC8148056
OpenAlexW3113194930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.